IceCure Medical (ICCM)
(Delayed Data from NSDQ)
$0.74 USD
0.00 (-0.27%)
Updated Jul 3, 2024 12:49 PM ET
After-Market: $0.73 -0.01 (-1.26%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ICCM 0.74 0.00(-0.27%)
Will ICCM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ICCM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ICCM
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade
ICCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Doximity (DOCS) Q4 Earnings and Revenues Surpass Estimates
ReWalk Robotics (LFWD) Reports Q1 Loss, Misses Revenue Estimates
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Lags Revenue Estimates
Other News for ICCM
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function
IceCure Medical announces data from ICESECRET kidney cancer trial